the brain; thus, the term "neuroproteinopathy" has been coined to describe these disorders. More specific terms such as "tauopathy" for PSP, CBD, and frontotemporal dementia (FTD) and "synucleinopathy" for PD, DLB, and MSA have been liberally applied. Various proteins accumulate abnormally both intracellularly (i.e., tau tangles, Lewy bodies) and extracellularly (i.e., plaques) and are linked to neurodegenerative diseases. Within a disorder there may be an overlap of protein pathology, such as the co-occurrence of amyloid-β plaques and Lewy bodies in DLB (►Fig. 2).
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To date, no reliable biomarkers have been established as diagnostic for any of the atypical parkinsonisms; however, ancillary brain imaging (as described in subsequent sections) is increasingly used as an adjunctive diagnostic tool in select cases. Although many features of the atypical parkinsonian syndromes overlap with those of PD, certain key features and "red flags" have been identified that can be helpful in distinguishing the atypical parkinsonisms (see ►Table 2, diagnostic criteria for PD from the Movement Disorders Society). 8 As in PD, core parkinsonian motor features must be present in atypical parkinsonisms, including bradykinesia in combination with either rest tremor, rigidity, or both. Although the absence or paucity of tremor is sometimes reported as a red flag for atypical parkinsonian syndromes, this finding is nonspecific and may also be observed in certain PD subtypes. Critically, the progression of symptoms in atypical parkinsonian syndromes differs from PD, with a relatively rapid functional decline with early gait impairment and falls (often requiring an assist device or wheelchair within 5 years of disease onset), and often with bulbar dysfunction with severe dysarthria, dysphonia, and dysphagia. Although a therapeutic response to dopaminergic therapy is typical in PD, in atypical parkinsonisms the response may be poor or absent, and adverse effects can be more significant. Motor fluctuations and levodopa-induced dyskinesias are uncommon in atypical parkinsonisms and support the diagnosis of PD when present. Additional "plus" features may include oculomotor abnormalities, early prominent dysautonomia, pyramidal tract or cerebellar signs (ataxia), dystonia (especially antecollis or dystonia leading to limb contractures), laryngeal stridor, myoclonus, alien-limb phenomenon, apraxia, and early dementia. Nonmotor features such as rapid eye movement (REM) sleep behavior disorder (RBD), restless leg syndrome, and periodic limb movements of sleep are not common in tau disorders such as PSP and CBD, whereas they are common in synucleinopathies such as PD.
Progressive Supranuclear Palsy
Progressive supranuclear palsy (PSP) was first described by Drs. Steele, Richardson, and Olszewski in 1963. 9 Approximately 5 to 6% of those presenting with parkinsonism are diagnosed with PSP, making it one of the most common forms of atypical parkinsonism. The estimated prevalence is $5 per 100,000 individuals, 10-12 and the reported annual incidence is 5.3 per 100,000 in men and women between the ages of 50 and 99. 13 However, these estimates are likely low due to underrecognition and misdiagnosis. Unlike PD, a diagnosis of PSP by general and movement disorders neurologists is correct in $75% of cases.
14 The most common misdiagnoses include PD and vascular parkinsonism, as well as the atypical parkinsonisms MSA and corticobasal syndrome (CBS). 15 Further complicating diagnosis is the recent recognition of the heterogeneous presentation of PSP and the identification of PSP variants. Classic PSP, or Richardson's syndrome, is characterized by early gait and postural instability, unexplained falls, supranuclear gaze palsy, axial rigidity, bradykinesia, dysarthric speech, and progressive dementia. The onset of symptoms in PSP typically occurs in the 60s, with an average age of onset between 63 and 66 years old and a mean survival of $5 to 9 years from disease onset.
A key feature of PSP that distinguishes it from other parkinsonian syndromes is the presence of early gait dysfunction and postural instability. Gait in PSP is often described as clumsy and stiff, and is characterized by step asymmetry and large lateral deviations sometimes described as "like a drunken sailor." Patients with PSP also pivot somewhat recklessly rather than turning en bloc as in PD, resulting in more instability and falls. Falls occur within the first year or two, and often lead to significant injury including bruises and fractures.
16 Falls can occur due to multiple factors including axial rigidity, Fig. 2 Clinicopathologic overlap exists among neurodegenerative proteinopathies including α-synuclein (synucleinopathy), tau (tauopathy), amyloid and TDP-43 pathology. AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; DLB, dementia with Lewy bodies; CBD, corticobasal degeneration; FTD, frontotemporal dementia; LPA, logopenic primary progressive aphasia; MND, motor neuron disease; MSA, multiple system atrophy; PSP, progressive supranuclear palsy. bradykinesia, freezing, reduced/absent postural reflex, visuovestibular deficits, and decreased insight. Indeed, patients with PSP who have lost insight into their postural instability can appear to "rocket" out of their chair recklessly instead of waiting for assistance, often prompting a fall. In addition to gait impairment, visual symptoms are also a hallmark of PSP. These include blurred vision, photosensitivity, diplopia, and difficulty reading due to both the inability to look down and due to convergence insufficiency. Vertical gaze impairment in general is often associated with PSP, but this is nonspecific and can be seen in other neurodegenerative disorders and normal aging.
17 By contrast, downgaze impairment is the most sensitive predictor for PSP, though both upgaze and horizontal ophthalmoparesis can progressively develop as well. Supranuclear gaze palsy can be overcome by changes in head position or oculocephalic maneuvers, but testing is often limited by axial rigidity. Slowed vertical saccades and reduction of optokinetic nystagmus are increasingly recognized as early signs and predictors of supranuclear gaze palsy in PSP. Squarewave jerks are also common and characterized by minisaccadic intrusions during fixation at a distance. In addition, patients may suffer from blepharospasm and apraxia of eye opening. This apraxia can in select cases result in functional blindness. Additional symptoms of PSP can include a change in personality, emotional withdrawal, and a characteristic facial appearance in which bradykinesia and dystonia combine with reduced eye blinking to produce a worried or astonished expression. Eyebrow furrowing (procerus contraction) and vertical wrinkling of the forehead are common, referred to as the "Procerus sign."
18 Bulbar symptoms include progressive dysarthria characterized by spastic, hypernasal, hypokinetic, and monotonous speech. Stuttering, echolalia, and occasional involuntary vocalizations may also be present, as well as an apraxia of phonation. In addition, progressive dysphagia occurs early and increases the risk of aspiration, pneumonia, and early death. Mood disturbance and cognitive decline are also frequent in PSP. Mood disturbance is primarily characterized by apathy more than depression, but may also include disinhibition, dysphoria, anxiety, irritability, and agitation.
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Pseudobulbar affect (laughing or crying incongruous with mood) can also occur with emotional lability or incontinence, is more common in PSP relative to other parkinsonian syndromes, and can be a cause of significant distress for both the patient and caregivers.
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Progressive supranuclear palsy is also associated with dementia. Similar to other parkinsonian syndromes, progressive frontal, subcortical dementia is typical and includes slowed processing, reduced verbal fluency, and executive dysfunction. Perseveration of automatic behaviors (such as that seen with the three-clap test or "applause sign") and grasping, imitative behaviors may also be present. Ideomotor apraxia occurs in both PSP and CBS, leading to confusion in diagnosis, but is more prominent in CBS.
21

Diagnosis: Distinguishing Novel PSP Variants
The National Institute of Neurological Disorders and Stroke and the Society for PSP International Workshop established diagnostic criteria for possible and probable PSP. They include progressive symptoms with onset after the age 40, postural instability, frequent falls, and slowed vertical saccades or vertical gaze palsy. 22 Definite PSP additionally requires pathological evidence. Supportive findings include symmetric rigidity, diminished response to levodopa, and early cognitive impairment, whereas exclusionary factors include encephalitis, focal brain lesion, hallucinations, prominent dysautonomia, and alien limb phenomenon. Although previously thought to be exclusionary, cerebellar features have recently been described in variant PSP.
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The diagnosis of classic PSP, or Richardson's syndrome, is relatively straightforward. However, the clinical presentation of PSP is increasingly recognized as heterogeneous and includes several clinical variants or phenotypes. 24 At least five phenotypic variants have been described: PSP-parkinsonism (PSP-P), PSP-pure akinesia gait freezing (PSP-PAGF), PSP-corticobasal syndrome (PSP-CBS), PSP-behavioral variant of FTD (PSP-bvFTD), and two other possible PSP variants with features that overlap with either primary lateral sclerosis (PSP-PLS) or cerebellar ataxia (PSP-C) (►Table 3).
Although the presentation of each PSP variant is different, they all progress to develop more typical PSP features, including postural instability, falls, and supranuclear gaze palsy, as well as classic tau pathology. PSP-Parkinsonism. The most common variant of PSP is PSP-parkinsonism, with features of tremor, asymmetric bradykinesia, and rigidity that mimic PD.
25 Ocular motility may be relatively normal early in the disease; however, slowed vertical saccades and reduced optokinetic nystagmus typically develop over time. Parkinsonism is frequently partially levodopa-responsive early on, with waning of response and the development of more typical PSP symptoms as the disease progresses. Mean survival for patients with PSP-parkinsonism is usually longer than in Richardson's syndrome, averaging 9 or more years from disease onset. PSP-Pure Akinesia with Gait Freezing (PSP-PAGF). PSP-PAGF was first described in 1974, and is characterized by progressive freezing of gait or speech (usually with initiation), frequent falls, micrographia, and facial hypomimia. 26, 27 Tremor is typically absent, and more classic signs of PSP such as rigidity, supranuclear palsy, and dementia develop much later in the disease course. Evidence of significant leukoaraiosis on brain imaging is exclusionary, and response to levodopa is typically poor or transient.
PSP-Corticobasal Syndrome (PSP-CBS).
PSP and CBD overlap both clinically and pathologically. Indeed, PSP pathology is reported in up to 40% of clinically diagnosed CBD cases. 28 A relatively rare variant of PSP, PSP-CBS presents initially like CBD with asymmetric rigidity, bradykinesia, dyspraxia, alien limb phenomenon, and dystonia. 29 Slowed saccades, particularly toward the more affected side, are common, as opposed to vertical gaze palsy. More classic features of PSP such as gait and postural instability develop later. PSP-Behavioral Variant Frontal Temporal Dementia (PSPbvFTD). Also rare, PSP-bvFTD often presents with behavioral and cognitive dysfunction. Typical PSP symptoms follow later, including gait difficulty, falls, supranuclear palsy, and levodopa-unresponsive parkinsonism.
30 Until other parkinsonian features develop, a misdiagnosis of frontal temporal dementia or other primary dementia is common.
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Progressive Supranuclear Palsy-Primary Lateral Sclerosis (PSP-PLS). PSP and primary lateral sclerosis (PLS) share common features, including bulbar symptoms and spastic gait. Although supranuclear gaze palsy is not usually present, ocular dysmotility is sometimes apparent in PLS. Recent reports suggest a possible PSP-PLS overlap syndrome, 32, 33 with tau pathology found in areas linked to the corticospinal tract.
34
Cerebellar Variant of PSP (PSP-C).
Increasing reports suggest a novel variant of PSP with features of cerebellar ataxia and tau pathology in the deep cerebellar nuclei.
23,35
Although still rare and underrecognized, based on recent reports PSP-C may be more prevalent in Asian populations.
The definition and variants of PSP continue to undergo revision, and new criteria are often being established. Respondek and colleagues recently proposed an approach to describing the phenotypic spectrum of PSP based on the predominant clinical features seen within the first 2 years of presentation.
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"Predominance types" were identified, including Richardson's syndrome, postural instability versus oculomotor predominant, parkinsonism, corticobasal syndrome, FTD, and unclassified. These predominance types, as well as "atypical" PSP variants, are still being validated.
Pathology
Progressive supranuclear palsy is pathologically characterized by abnormal tau deposition and associated pathology (►Fig. 3). The hallmark of PSP is the tufted astrocyte, but the pathology includes also neurofibrillary tangles, pretangles, and coiled bodies. 36 Tau pathology is typically present in the basal ganglia, pons, and oculomotor nuclei, and usually spares the cortex. There is associated gliosis and degeneration marked by loss of pigmented cells in the substantia nigra, and progressive atrophy of the midbrain, subthalamic nucleus, superior cerebellar and middle cerebellar peduncles, dentate, and frontal cortex. Abnormal deposition of hyperphosphorylated tau is characteristic of the "tauopathies," including PSP, CBD, AD, and FTD. The tau protein is encoded by MAPT (17q21) and has six isoforms that include three or four repeat (R) domains that bind microtubules. In PSP and CBD, the ratio of 4R:3R tau in brain is increased compared with unaffected individuals, whereas in frontotemporal dementia 3R tau is predominant. Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches McFarland, Hess 219
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Although MAPT variants are closely linked to parkinsonisms including PSP, specific MAPT mutations are rare in PSP. In addition to MAPT, recent genome-wide association studies identified novel variants and putative genes associated with PSP, including STX6 (encodes syntaxin 6), EIF2AK3 (PERK), and MOBP (myelin-associated oligodendrocytic basic protein). 37 Efforts are underway to validate these genes and their potential role in PSP (and other tauopathies).
Diagnostic Modalities and Biomarkers
Brain imaging has been the most useful adjunctive diagnostic tool for PSP to date. The midbrain and superior cerebellar peduncles are typically atrophied in PSP, which can help distinguish it from other parkinsonian disorders. [38] [39] [40] [41] [42] [43] Several methodologies have been proposed to measure midbrain atrophy on magnetic resonance imaging (MRI), including measurement of the suprapontine midline anteroposterior (AP) diameter versus the midsagittal area of the midbrain tegmentum and the ratio of these measurements to the pons size. The midbrain:pons ratio is significantly reduced compared with that in PD, MSA-parkinsonism, and healthy controls. 38 The midsagittal view of the brainstem in PSP consequently takes on a beaked appearance like a "hummingbird" or "penguin body" (►Fig. 4). 38, 39 Superior cerebellar atrophy can also be assessed and compared with the size of the middle cerebral peduncle. 44 In addition, both gray and white matter reductions, in particular in the anterior and medial thalamic nuclei, can be detected by diffusion tensor imaging. 45 Positron emission tomography (PET) is also increasingly being used, and shows hypometabolism in the frontal cortex, cingulate, caudate, thalamus, and midbrain. 
Therapeutic Strategies
The treatment of PSP remains primarily symptomatic and should utilize a multidisciplinary team approach, including physical and occupational therapists, speech pathology, neuropsychology, psychiatry, social work, and palliative care. Physical and occupational therapy are critical to prevent falls, maintain mobility, and help with activities of daily living. Speech therapy early on focuses on dysarthria and may include cognitive therapy for speech apraxia. As speech becomes more dysarthric or anarthric, alternative means of communication may be needed. Dysphagia develops early in PSP relative to PD, increasing aspiration risk, morbidity, and mortality. Early and regular swallowing evaluations are critical to assess aspiration risk and to intervene with swallow therapy or modify diet. In advanced disease, the question of a feeding tube may arise. The decision to place a feeding tube should be discussed early with the patient, family/caregiver, and speech pathologist. Importantly, although a percutaneous gastrostomy tube can help with nutrition, hydration, and medication administration, it does not reduce the risk of aspiration or change the overall disease prognosis. Ethical, cultural, and personal considerations regarding quality of life are important to discuss when deciding whether gastrostomy is appropriate. Palliative care options should be discussed, in addition to a frank discussion of advanced care directives. A social worker or case manager is often helpful to discuss care planning and needs with patients, family, and caregivers.
Drug therapy for PSP, while limited, focuses on symptoms (see ►Table 4 for summary). Parkinsonism may respond to carbidopa-levodopa, but often doses up to 300 mg 3 to 4 times daily for a few months are required to determine responsiveness. PSP-parkinsonism in particular can respond to levodopa initially, whereas Richardson's syndrome and other variants are more often refractory. Dopamine agonists typically provide minimal benefit in PSP. Limited evidence suggests that amantadine may help gait and dysphagia. 48 Alternative therapies include the supplement coenzyme Q10, which has been shown in a small randomized clinical trial to provide modest benefit in PSP, including slight improvement in cognitive function. 49 More recently, a larger trial of treatment with coenzyme Q10 2400 mg daily showed no benefit compared with placebo, 50 though this trial was limited by a high dropout rate of nearly 40%. Painful dystonic posturing of the neck and limbs, blepharospasm, and eye-opening apraxia can be treated with botulinum toxin. For cognitive decline and dementia, cholinesterase inhibitors such as rivastigmine provide only modest benefit. Mood disturbance, when identified, may include depression, anxiety, and irritability, and should be treated with antidepressants. Some selective serotonin reuptake inhibitors may worsen apathy; instead, practitioners may consider more activating antidepressants such as bupropion, venlafaxine, sertraline, or fluoxetine. For pseudobulbar affect, dextromethorphan-quinidine may be helpful if refractory to antidepressant therapy. Marked midbrain atrophy is present suggesting the appearance of a "hummingbird" or "penguin" sign. Note also cortical atrophy that is frontalpredominant.
Corticobasal Syndrome
Corticobasal (or cortico-basal ganglionic) degeneration classically describes an atypical parkinsonian syndrome that presents with asymmetric parkinsonism, dystonia, and ideomotor apraxia. The term corticobasal syndrome is increasingly used during life to describe the clinical presentation thought initially to be specific to CBD, but has been shown to occur due to other neuropathologies, including Alzheimer's disease and even PSP. Most commonly however, patients present with marked asymmetric hand dysfunction, followed by bradykinesia, tremor, rigidity, and a frontal syndrome. 51 Additional features include a coarse rest/action tremor; limb dystonia resulting in contractures; alien limb phenomenon; hand, limb, gait, or speech apraxia; myoclonus; cortical sensory loss; language deficits; frontal/cortical dementia; supranuclear gaze palsy; dysarthria/dysphagia; gait and postural instability; and hyperreflexia with extensor plantar responses. Onset of disease generally occurs in the mid-60s, and prognosis is often poor, with a mean survival of $7 years from diagnosis. Features somewhat unique to CBS include ideomotor apraxia, myoclonus, and alien limb phenomenon. 52 Inability to perform a skilled motor task with intact language, motor, and sensory function defines ideomotor apraxia. Examples include inability to imitate gestures or mime a certain task (e.g., cut with a pair of scissors or show a Victory sign). As symptoms progress, limb-kinetic apraxia, which is independent of modality (imitation vs. miming) may become prominent and difficult to distinguish from ideomotor apraxia. Alien limb typically manifests as spontaneous levitation of an arm or leg, but can also include abnormal grasping, posturing, or pursuit versus avoidance of a tactile stimulus in the contralateral limb. Dementia in CBS is a later feature, and sematic memory is often preserved. 53 Neuropsychiatric testing demonstrates deficits in attention, concentration, verbal fluency, language, praxis, and executive and visuospatial function. 54 Other cortical findings such as aphasia, limb apraxia, and graphesthesia depend on the predominant hemisphere affected. Clinical criteria for the diagnosis of CBS have evolved with the recognition of variants and diverse pathology. In 2013, Armstrong and colleagues proposed new diagnostic criteria for CBS including four phenotypes: classic CBS, frontal behavioralspatial syndrome, nonfluent/agrammatic primary progressive aphasia (naPPA), and a PSP syndrome. 28 Probable and possible criteria were described for CBS, and include insidious onset, gradual progression of symptoms for more than 1 year, and age of onset 50 years or more, with or without a similar family history or known tau mutations. 28 The frontal behavioral variant of CBS involves executive dysfunction as well as behavioral or personality changes. Progressive nonfluent/agrammatic PPA is characterized by effortful, agrammatic speech with impaired grammar/sentence comprehension and groping, or distorted speech production (i.e., apraxia of speech). The PSP-CBS, as expected, includes axial or symmetric limb rigidity/ akinesia, postural instability, falls, urinary incontinence, behavioral changes, and supranuclear vertical gaze palsy.
Pathology
Corticobasal syndrome (as CBD) has classically been considered a distinct clinicopathological entity, but more recently it has been shown to have different pathologies. Indeed, classic CBD pathology is found in only 25 to 56% of suspected CBS cases. 28 Corticobasal degeneration pathology is characterized by widespread neurodegeneration, and despite the typical asymmetric clinical presentation, involves both cortical hemispheres including the basal ganglia, thalamus, substantia nigra, subthalamic nucleus, and red nucleus. As in PSP, widespread 4R-predominant tau pathology is present in neurons and glia. Although tufted astrocytes are typically absent, "coiled bodies" are frequent in oligodendroglia, as well as in astrocytic plaques and corticobasal inclusions. 55 Intranuclear inclusions in subcortical nuclei such as the substantia nigra are characteristic of globose neurofibrillary tangles, whereas those in the cortex are granular, crescent-shaped, or globular.
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Diagnostic and Therapeutic Strategies
To date, there are no specific diagnostic biomarkers for CBS. Neuroimaging findings such asymmetric frontoparietal atrophy seen on computed tomography (CT)/MRI, however, may be helpful in differentiating CBS from other parkinsonian syndromes. 57 Functional imaging such as [F 18 ]fluorodeoxyglucose positron emission tomography (FDG-PET) may also reveal asymmetric cortical metabolism. Similarly, striatal uptake on [ imaging, similar to a DaTSCAN) are reduced and asymmetric, consistent with dopaminergic denervation, although these findings are not specific to CBS. In addition, both tau and β-amyloid ligands are being explored to diagnose and differentiate CBS from other disorders.
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The treatment of CBS remains primarily supportive. Similar to PSP, a multidisciplinary approach involving rehabilitation services and palliative care is critical to maintain function and comfort despite continued disease progression. Regular exercise and activity early in the disease helps with independent mobility and may delay disability. Although dopaminergic therapy rarely provides improvement in classic CBS, a levodopa trial up to 250 to 300 mg administered 3 to 4 times daily should in most cases be attempted, as it sometimes provides partial benefit for rigidity. Muscle relaxants (e.g., baclofen) and botulinum toxin can help painful rigidity and dystonic (contractures) that may limit function. Myoclonus in CBS is typically cortical and may respond to levetiracetam or clonazepam, but should only be treated if bothersome.
Multiple System Atrophy
Multiple system atrophy is an adult-onset, sporadic, progressive, multisystem, neurodegenerative disease characterized by a variable expression of parkinsonism, cerebellar and pyramidal signs, and autonomic dysfunction. First described in the 1960s, MSA has been called a variety of names, including striatonigral degeneration (SND), Shy Drager syndrome, and olivopontocerebellar atrophy, depending on the predominant presenting symptoms. 59 The discovery of pathological oligodendroglial cytoplasmic inclusions and multisystem neurodegeneration regardless of the clinical phenotype, however, suggests a common pathology; thus, the current nomenclature can be confusing even to experts. The current consensus statement on MSA now recognizes two clinical phenotypes: MSA-P, which is distinguished by predominant parkinsonism, and multiple system atrophy-cerebellar (MSA-C), which has dominant cerebellar features. 60 The prevalence of MSA is similar to PSP, estimated at 3.4 to 4.9 cases per 100,000 individuals. 61 The median age of onset for MSA is earlier at 58 years old, and the cutoff for early diagnosis is 40 years old. Disease progression is generally more rapid than in PD, and the mean survival is 6 to 10 years, 62,63 consistent with more widespread neurodegeneration.
Clinical Features
Although MSA-P presents with predominant parkinsonism, there are several features that distinguish it from PD. In contrast to the typical pill-rolling type of tremor typically seen in PD, tremor in MSA-P is often higher in frequency and lower in amplitude with a jerky, stimulus-sensitive myoclonic postural/action component. 64 Parkinsonism in MSA is further differentiated from PD by its more symmetrical appearance, dystonia (axial and appendicular), early dysarthria/dysphonia, gait and postural instability (though later compared with that in PSP), rapid progression, and autonomic dysfunction. Speech is often characterized by a mixed spastic, hypokinetic dysarthria with a vocal flutter or dysphonia. Dysphagia also occurs earlier and is more severe than in PD. Some patients may also develop respiratory or laryngeal stridor requiring continuous positive airway pressure. Other features include hyperreflexia, disproportionate anterocollis, and early striatal deformities. Parkinsonism in MSA may initially respond to dopaminergic therapy, but often doses are limited by side effects including exacerbation of orthostatic symptoms and dyskinesia (in particular, orofacial dyskinesia and dystonia). Multiple system atrophy-C is one of the most common causes of sporadic, adult-onset ataxia, occurring in the setting of parkinsonism, autonomic dysfunction, and a relatively rapid progression compared with PD. 64 In MSA-C, cerebellar dysfunction manifests as gait and balance impairment, limb ataxia, dysarthria, and oculomotor dysmetria (hypometric/hypermetric saccades, jerky pursuits, and nystagmus). Features common to both subtypes of MSA include sleep disturbances (i.e., sleep apnea, RBD, and respiratory and autonomic dysfunction, which can precede motor signs by several months to years. 65 Orthostatic hypotension is common and frequently exacerbated by treatment. Urogenital dysfunction is manifested by incomplete bladder emptying or urinary frequency/urgency/incontinence, particularly in women, and erectile dysfunction in men. Additional features can include Pisa syndrome, dystonic lateral flexion of the spine, abnormal forward truncal flexion (camptocormia), respiratory insufficiency, and pseudobulbar affect.
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These red flags may help to distinguish MSA from PD (►Table 5). Cognitive dysfunction and dementia are also increasingly recognized in MSA.
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Pathology
Multiple system atrophy is characterized by oligodendroglial cytoplasmic inclusions that are enriched with α-synuclein and correlate with the severity of neuronal loss and disease duration. 68 Neurodegeneration and gliosis are widespread and involve the putamen, substantia nigra, pons, inferior olivary nucleus, cerebellum, and brainstem. 69 The degree of abnormalities found in the nigrostriatal system, pons, and cerebellum correlate with the subtype of MSA. For example, the pathology of the dorsal motor nucleus of the vagus, locus coeruleus, ventrolateral medulla, and intermediolateral cell columns of the spinal cord has been associated with autonomic dysfunction.
Diagnostic and Therapeutic Strategies
Adjunctive diagnostic testing may aide in the distinction of MSA from PD and other parkinsonian syndromes. Although serum biomarkers such as α-synuclein-total, phosphorylated, and oligomeric forms-remain controversial, neuroimaging can be helpful along with careful clinical assessment. 70 Brain MRI in MSA-P may demonstrate T2 hypointensity in the posterolateral putamen, representing neurodegeneration and iron deposition, and slit hyperintensity at the lateral margin of the putamen. 71, 72 In MSA-C olivopontocerebellar atrophy is predominant, and pontine atrophy and gliosis may manifest as a "hot cross bun" pattern on T2 imaging (►Fig. 5).
Also, PET and SPECT imaging have been shown to help with MSA diagnosis; they show decreased metabolism and reduced binding of 125 I-ioflupane in the striatum. 73 Voxel-based morphometry and functional MRI demonstrate reduced volumes in the basal ganglia, cerebellum, and pons in MSA compared (orofacial) and other side effects may limit therapy. Dopamine agonists can be used as a second-line treatment, but are generally inferior to levodopa for MSA and have not been carefully studied. Recently, rasagiline has been studied in MSA-P, but failed to show a benefit as assessed by the Unified MSA Rating Scale. 77 Amantadine is another option for the treatment of parkinsonism in MSA, but lacks strong evidence and the potential adverse effects may be relatively high.
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Deep brain stimulation is generally not recommended in MSA due to poor response despite occasionally reducing tremor or dyskinesia. The treatment of autonomic dysfunction such as orthostatic hypotension should include conservative measures such as oral hydration, increased salt intake, and compression stockings/ abdominal binders. Pharmacological options include fludrocortisone (0.1 mg 1-3/d), which increases blood volume, but may be contraindicated in heart failure patients. Midodrine (2.5-10 mg) and droxidopa (100-300 mg) given 2 to 3 times daily can also be used to treat neurogenic orthostatic hypotension, but have the potential to cause supine hypertension. Pyridostigmine is an alternative that increases blood pressure without supine hypertension, but may have a modest effect and requires high doses that result in intolerance. Octreotide can be used for postprandial hypotension. For neurogenic bladder, antispasmodics (e.g., oxybutynin) or botulinum toxin injections can be helpful. Intermittent self-catheterization or the placement of a suprapubic catheter may be required in some patients. Sleep apnea and inspiratory stridor benefit from noninvasive ventilation by continuous positive airway pressure.
Dementia with Lewy Bodies
Dementia with Lewy bodies is the second most common form of neurodegenerative dementia after AD, and has similar features to other dementias including PD dementia (PDD). Indeed, DLB is of the PD disease spectrum and is characterized by its early-onset, rapidly progressive dementia. The clinical criteria for DLB include (1) parkinsonism that is coincident with or follows the onset of dementia, (2) mental status fluctuations, and (3) recurrent visual hallucinations. 79 Additional features include gait instability, falls, orthostatic hypotension (sometimes causing confusion with MSA), RBD, depression, delusions/paranoia (psychosis), and neuroleptic sensitivity.
Pathology
The pathological hallmark of DLB (and similarly in PDD) is diffuse Lewy bodies, characterized by intracellular inclusions enriched with α-synuclein (►Fig. 6). Incidental Lewy body pathology is found at autopsy in 10 to 12% of healthy individuals without signs of parkinsonism and may indicate preclinical disease. [80] [81] [82] The degree of cortical Lewy body pathology in DLB correlates well with dementia severity.
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Spread of Lewy body pathology, or synucleinopathy, from brainstem to neocortex as described by Braak and colleagues is thought to contribute to progressive cognitive impairment.
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Most cases of DLB (and PDD) have concurrent Alzheimer's-type pathology that likely also contributes to dementia.
85
Diagnostic and Therapeutic Strategies
Developing neuroimaging biomarkers currently hold the most promise for distinguishing DLB from AD and other parkinsonian syndromes. 86 Brain MRI typically demonstrates diffuse cerebral atrophy with relative preservation of occipital and mesiotemporal lobes compared with that seen in AD. 87 Functional imaging such as SPECT and PET may also help discriminate DLB from AD and show occipital hypoperfusion. In addition, preserved metabolism of the posterior cingulate gyrus relative to the precuneus on FDG-PET has recently been shown to correlate with DLB and is coined the "cingulate island" sign. 88 Dopaminergic imaging (i.e., DAT SPECT), while nonspecific, may be abnormal in early DLB and demonstrate nigrostriatal denervation. Likewise, amyloid burden can be assessed with PiB (Pittsburgh compound B) scanning, and associates more with PDD than DLB. 89 In addition to imaging, cerebrospinal fluid analysis of tau and α-synuclein levels may be useful in differentiating DLB from AD.
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As with other atypical parkinsonian syndromes, the treatment of DLB is primarily symptomatic and requires a multidisciplinary team approach. Parkinsonism in DLB typically responds to levodopa; however, treatment must be balanced against the potential for exacerbating psychosis and hallucinations. Dopaminergic agonists are not preferred, and nondopaminergic agents such as monoamine oxidase inhibitors, amantadine, and anticholinergics are often avoided due to their potential to cause confusion and worsen psychosis. First-line treatment for hallucinations and psychosis is reduction in dopaminergic medications, but if necessary, atypical antipsychotics are added. Frequently, quetiapine is used and can be helpful to reduce agitation associated with sundowning, but studies do not support its efficacy for hallucinations. Clozapine has been shown to be effective, but requires routine blood monitoring for agranulocytosis and may exacerbate orthostatic hypotension and depression. 91 Pimavanserin, a selective 5-HT 2 inverse agonist, has recently been approved by the Food and Drug Administration for the treatment of psychosis in PD, but not DLB. 92 Cognitive impairment and fluctuations in DLB benefit from treatment with cholinesterase inhibitors such as rivastigmine and donepezil. 93 Comorbid depression, apathy, and anxiety should also be treated if identified.
Conclusions
Although there is considerable overlap of features between the atypical parkinsonian syndromes and PD, attention to historical details (such as mode of presentation and the rate of disease progression) and specific clinical features or red flags may aide in the differentiation of these overlapping entities. Revision of clinical criteria to better encompass the clinical heterogeneity and the varied phenotypes of these syndromes may also help with diagnosis, and will become increasingly important with the emergence of novel therapies. Understanding of the clinicopathological correlates and the development of novel diagnostic biomarkers will help further efforts toward disease-modifying therapeutics for both PD and the atypical parkinsonian syndromes.
